Genitourinary Cancer News

SAN FRANCISCO — The combination of fam-trastuzumab deruxtecan-nxki and nivolumab demonstrated antitumor activity among patients with HER2-expressing urothelial carcinoma, according to results presented at ASCO Genitourinary Cancers Symposium.

American Association for Cancer Research released a first-of-its-kind report detailing the impact of the COVID-19 pandemic on the cancer community, both in patient care and research practice.

Patients with cancer had few differences in reported adverse events compared with people without cancer after receiving COVID-19 vaccines, according to study results published in JNCCN — Journal of the National Comprehensive Cancer Network.

Older patients with cancer benefited from single-agent immune checkpoint inhibitors but had higher rates of adverse events and therapy discontinuation with increasing age, according to results of a retrospective study in JAMA Oncology.

Germline microRNA-based biomarkers accurately predicted grade 2 or higher immune-related adverse events associated with anti-PD-1/PD-L1 therapy among patients with various cancer types, according to study results.

Trial-ineligible patients with advanced cancer appeared nearly twice as likely as trial-eligible patients to receive immunotherapy, despite no evidence of a survival benefit compared with chemotherapy for this population.

President Joe Biden has unfinished business with cancer.

Balstilimab plus zalifrelimab demonstrated promising and durable activity among women with recurrent and/or metastatic cervical cancer who relapsed after platinum-based therapy, according to a phase 2 study in Journal of Clinical Oncology.

PSA testing rates increased after the U.S. Preventive Services Task Force revised its guidance on prostate cancer screening in 2017, according to results of a large national cohort study in JAMA Oncology.

Residents of rural areas demonstrated higher levels of cancer fatalism and cancer information overload than urban residents, according to a study in Cancer Epidemiology, Biomarkers & Prevention.